Abstract：
OBJECTIVE: Aim: To investigate the effectiveness of rifaximin and probiotics for the correction of intestinal permeability in patients with metabolic-associated fatty liver disease (MAFLD) in combination with type 2 diabetes mellitus.
METHODS: Materials and Methods: The prospective interventional randomized investigation included 68 patients with MAFLD in combination with type 2 diabetes, who were examined and divided into the 2 groups of treatment.
RESULTS: Results: The serum levels of interleukin (IL) - 6, IL-10 and zonulin, indicators of liver functional activity, liver attenuation coefficient between treatment group vs. control group after 2 weeks, 1 month, 3 and 6 months of therapy were significant differed. The serum levels of IL-6 and zonulin significantly decreasing and increasing of IL-10 in the treatment group after 2 weeks, 1, 3 and 6 months of combined therapy. When comparing of stool short-chain fatty acids concentration between treatment group vs. control group after 2 weeks, 1 month, 3 and 6 months of therapy the levels of acetic, butyric and propionic acids significantly differences and increase in their levels were established.
CONCLUSIONS: Conclusions: The results of the study in dynamics during 6 months show that the additional appointment of rifaximin, multispecies probiotic and prebiotic to metformin in patients with MAFLD and type 2 diabetes led to the elimination of subclinical inflammation, modulation of the permeability of the intestinal barrier and lowering increased intestinal permeability, as well as to the lower serum activity of liver aminotransferases and decrease the stage of steatosis.
METHODS: Materials and Methods: The prospective interventional randomized investigation included 68 patients with MAFLD in combination with type 2 diabetes, who were examined and divided into the 2 groups of treatment.
RESULTS: Results: The serum levels of interleukin (IL) - 6, IL-10 and zonulin, indicators of liver functional activity, liver attenuation coefficient between treatment group vs. control group after 2 weeks, 1 month, 3 and 6 months of therapy were significant differed. The serum levels of IL-6 and zonulin significantly decreasing and increasing of IL-10 in the treatment group after 2 weeks, 1, 3 and 6 months of combined therapy. When comparing of stool short-chain fatty acids concentration between treatment group vs. control group after 2 weeks, 1 month, 3 and 6 months of therapy the levels of acetic, butyric and propionic acids significantly differences and increase in their levels were established.
CONCLUSIONS: Conclusions: The results of the study in dynamics during 6 months show that the additional appointment of rifaximin, multispecies probiotic and prebiotic to metformin in patients with MAFLD and type 2 diabetes led to the elimination of subclinical inflammation, modulation of the permeability of the intestinal barrier and lowering increased intestinal permeability, as well as to the lower serum activity of liver aminotransferases and decrease the stage of steatosis.
摘要：
目的：目的：探讨利福昔明和益生菌对代谢相关脂肪性肝病（MAFLD）合并2型糖尿病患者肠道通透性的影响。
方法：材料与方法：前瞻性干预随机调查共纳入68例MAFLD合并2型糖尿病患者，他们被检查并分为2组治疗。
结果：结果：血清白细胞介素（IL）-6，IL-10和zonulin，肝功能活动的指标，治疗组之间的肝脏衰减系数与对照组2周后,1个月,3和6个月的治疗有显著差异。2周后,治疗组血清IL-6、连蛋白水平显著降低,IL-10水平显著升高,1、3和6个月的联合治疗。当比较治疗组与治疗组之间的粪便短链脂肪酸浓度时对照组2周后,1个月,3和6个月的治疗乙酸的水平，确定了丁酸和丙酸的显着差异和水平的增加。
结论：结论：6个月内的动力学研究结果表明，额外服用利福昔明，MAFLD和2型糖尿病患者对二甲双胍的多品种益生菌和益生元导致亚临床炎症的消除，调节肠屏障的通透性并降低增加的肠通透性，以及降低肝脏转氨酶的血清活性和降低脂肪变性的阶段。
方法：材料与方法：前瞻性干预随机调查共纳入68例MAFLD合并2型糖尿病患者，他们被检查并分为2组治疗。
结果：结果：血清白细胞介素（IL）-6，IL-10和zonulin，肝功能活动的指标，治疗组之间的肝脏衰减系数与对照组2周后,1个月,3和6个月的治疗有显著差异。2周后,治疗组血清IL-6、连蛋白水平显著降低,IL-10水平显著升高,1、3和6个月的联合治疗。当比较治疗组与治疗组之间的粪便短链脂肪酸浓度时对照组2周后,1个月,3和6个月的治疗乙酸的水平，确定了丁酸和丙酸的显着差异和水平的增加。
结论：结论：6个月内的动力学研究结果表明，额外服用利福昔明，MAFLD和2型糖尿病患者对二甲双胍的多品种益生菌和益生元导致亚临床炎症的消除，调节肠屏障的通透性并降低增加的肠通透性，以及降低肝脏转氨酶的血清活性和降低脂肪变性的阶段。
